SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001213900-21-002479
Filing Date
2021-01-15
Accepted
2021-01-15 14:14:29
Documents
68
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-K rasp-20200930.htm   iXBRL 10-K 1838998
2 GRAPHIC imgnhouagydll512055352.jpg GRAPHIC 33291
8 EXHIBIT 21 ex21_1.htm EX-21 1855
9 EXHIBIT 31.1 ex311_2.htm EX-31.1 19027
10 EXHIBIT 31.2 ex312_3.htm EX-31.2 18589
11 EXHIBIT 32.1 ex321_4.htm EX-32.1 10969
12 EXHIBIT 32.2 ex322_5.htm EX-32.2 12068
  Complete submission text file 0001213900-21-002479.txt   7647066

Data Files

Seq Description Document Type Size
3 DEFINITION rasp-20200930_def.xml EX-101.DEF 271516
4 PRESENTATION rasp-20200930_pre.xml EX-101.PRE 475170
5 CALCULATION rasp-20200930_cal.xml EX-101.CAL 75551
6 LABEL rasp-20200930_lab.xml EX-101.LAB 897926
7 SCHEMA rasp-20200930.xsd EX-101.SCH 57323
13 EXTRACTED XBRL INSTANCE DOCUMENT rasp-20200930_htm.xml XML 1024476
Mailing Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170 646-396-4087
Rasna Therapeutics Inc. (Filer) CIK: 0001582249 (see all company filings)

IRS No.: 392080103 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 10-K | Act: 34 | File No.: 333-191083 | Film No.: 21531357
SIC: 2834 Pharmaceutical Preparations